Relationship between clinical outcomes and unintentional pulmonary vein isolation during substrate ablation of atrial fibrillation guided solely by complex fractionated atrial electrogram mapping  by Iriki, Yasuhisa et al.
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Summary
Background:  Controversy  exists  as  to  whether  atrial  ﬁbrillation  (AF)  ablation  guided  solely
by complex  fractionated  atrial  electrogram  (CFAE)  has  a  good  outcome  despite  not  requiring
pulmonary  vein  isolation  (PVI).
Objectives:  The  purpose  of  this  study  was  to  evaluate  the  effectiveness  of  AF  ablation  guided
solely by  targeting  CFAE  areas,  and  to  determine  whether  its  clinical  efﬁcacy  has  any  relationship
with unintentionally  isolating  the  PV.
Methods:  We  studied  100  consecutive  patients  (ages  59  ±  11  years;  54  with  paroxysmal,  35
persistent, and  11  long-standing  persistent  AF),  who  underwent  CFAE-ablation.  PV  potential
(PVP) was  recorded  before  and  after  ablation.  After  excluding  39  patients  in  whom  sinus  rhythm
could not  be  maintained  before  ablation  by  internal  cardioversion  and/or  who  had  a  history  of
PVI(s), PVPs  were  analyzed.
Results:  AF  was  terminated  during  ablation  in  98%  of  paroxysmal,  80%  of  persistent,  and  55%
of long-standing  persistent  AF  patients.  Nifekalant  (0.3—0.6  mg/kg)  was  administered  in  30%,
57%, and  83%,  respectively.  The  common  areas  of  CFAE  around  the  PVs  were  anterior  to  the
right PVs,  posterior  to  the  left  PVs,  and  at  the  ridge  of  the  left  atrial  appendage.  Among
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215  PVs  in  61  patients  (42  paroxysmal,  19  persistent),  only  17  PVs  (8%)  were  unintentionally
isolated.  The  atrial  potential  to  PVP  was  prolonged  (>30  ms)  in  13%  of  PVs.  After  at  least  12
months of  follow-up  (23  ±  5  months),  65%  of  paroxysmal  (11%  with  drug),  54%  of  persistent  (37%
with drug),  and  45%  of  long-standing  (60%  with  drug)  AF  patients  were  free  from  atrial  arrhythmia
after one  session.
Conclusions:  CFAE-ablation  terminates  AF  without  isolating  PVs  in  a  high  percentage  of  patients,
outcomes.
ardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
Fourteen  patients  had  a  history  of  PVI.  The  patient  charac-
teristics  are  shown  in  Table  1.
All  antiarrhythmic  drugs  were  discontinued  at  least  5
half-lives  before  the  study,  with  the  exception  of  amio-
darone,  which  was  discontinued  at  least  3  months  before  the
study.  All  patients  provided  written  informed  consent  for  the
procedure.  The  study  protocol  was  approved  by  the  insti-
tutional  ethics  committee.  AF  was  deﬁned  in  accordance
with  the  2007  Heart  Rhythm  Society  Expert  Consensus  State-
ment  [26]. Paroxysmal  AF  was  deﬁned  as  recurrent  AF  (≥2
episodes)  that  terminates  spontaneously  within  7  days.  Per-
sistent  AF  was  deﬁned  as  AF  that  is  sustained  for  more  than  7
days  or  as  AF  lasting  less  than  7  days,  but  necessitating  phar-
macologic  or  electrical  cardioversion.  And  AF  lasting  more
than  1  year  was  deﬁned  as  long-standing  persistent  AF.
We  excluded  patients  who  were  absent  of  PVP  in  all  4
veins  due  to  previous  PVI(s).  We  also  excluded  patients  who
could  not  be  maintained  in  SR  before  ablation  by  a  cardiover-
sion  due  to  difﬁculty  recording  PVP  before  ablation.
Mapping  and  ablation  of  AF
The  following  AF  ablation  technique,  described  by  Nadema-
nee  et  al.  [7,16,17]  was  utilized  for  this  study.  Initially,  an
8-mm  NaviStar  catheter  (Biosense  Webster,  Inc.,  Diamond
Bar,  CA,  USA)  was  used  until  April  2009,  when  we  switched
to  a  3.5-mm  NaviStar  ThermoCool  catheter  (Biosense  Web-
ster)  that  became  available  in  Japan.  In  brief,  after  coronary
sinus  (CS)  was  cannulated  by  decapolar  catheter  (Inquiry
Luma-Cath,  St.  Jude  Medical,  Irvine,  CA,  USA)  for  record-
ing  and  induction,  patients  underwent  non-ﬂuoroscopic
electroanatomic  mapping  with  the  CARTO  mapping  system
(Biosense  Webster)  at  least  5  half-lives  after  cessation  of
Table  1  Patient  characteristics.
Age,  years  59  ±  11
Sex,  men/women  82/18
Paroxysmal/persistent/long-standing  54/35/11
Structural  heart  disease
Hypertrophic  cardiomyopathy  4
Nonischemic  cardiomyopathy  3
Coronary  artery  disease  4
Hypertensive  heart  disease  (LV  mass
index  >  125  g/m2)
18
Congenital  heart  disease  (ECD,  TOF)  2
Valvular  heart  disease  (DVR,  MVR)  2and yields  excellent  clinical  
© 2011  Japanese  College  of  C
Introduction
Catheter  ablation  is  an  effective  approach  for  the  man-
agement  of  patients  with  atrial  ﬁbrillation  (AF)  [1—7].
Pulmonary  vein  isolation  (PVI)  is  one  of  the  most  common
strategies  for  ablation  of  paroxysmal  AF,  but  the  outcome
of  PVI  alone  for  patients  with  persistent  AF  is  poor  [8—10].
Additional  approaches,  such  as  linear  ablation  after  PVI  have
been  reported  [11—15].
Nademanee  et  al.  recently  described  a  different
approach  for  AF  ablation.  This  strategy  involved  identifying
the  target  ‘‘substrate’’  sites  using  electroanatomic  map-
ping  of  complex  fractionated  atrial  electrograms  (CFAEs)
[7,16,17].  Although  PVI  was  not  required  with  this  approach,
AF  ablation  guided  solely  by  CFAE  resulted  in  a  high  rate  of
success  in  maintaining  sinus  rhythm  (SR)  in  patients  with
either  paroxysmal  or  persistent  AF.  However,  results  of  the
study  by  Nademanee  et  al.  were  not  replicated  by  others
[6,18,19].  Thus,  the  role  of  CFAE-ablation  in  treating  AF
patients  remains  controversial.
Whether  CFAE  areas  act  as  an  AF  substrate  is  also  a  sub-
ject  of  debate.  Although  some  studies  have  reported  that
areas  of  CFAE  act  as  an  AF  substrate  [7,14]  and  represent
local  micro-reentrant  circuits  acting  as  focal  drivers  of  AF
[20,21],  other  studies  have  shown  that  CFAEs  are  caused  by
increased  autonomic  nerve  stimulation  from  epicardial  gan-
glionic  plexi  that  innervate  the  atrium  and  PVs  and,  in  turn,
trigger  and/or  maintain  AF  [22—25].
Despite  these  data,  it  is  unclear  what  proportion  of
patients  with  AF  can  be  terminated  with  this  approach  in
clinical  practice,  and  whether  unintentional  PVI  can  occur
during  CFAE-ablation.  Thus,  we  conducted  this  study  to
evaluate  how  CFAE-guided  ablation  as  the  sole  strategy
for  AF  ablation  affects  the  rate  of  AF  termination,  and
to  determine  the  long-term  outcomes.  Additionally,  our
goal  was  to  determine  and  characterize  PV  potential  (PVP)
before  and  after  AF  ablation  guided  by  CFAE,  and  to  deter-
mine  its  relationship  between  the  clinical  outcomes  and
PVI.
Methods
Study  population  and  protocol
This  study  comprised  100  consecutive  patients  (18  women
and  82  men;  mean  age,  59  ±  11  years),  including  54  (54%)
patients  with  paroxysmal  AF,  35  (35%)  patients  with  persis-
tent  AF,  and  11  (11%)  patients  with  long-standing  persistent
AF  with  symptomatic  drug  refractory  AF,  who  success-
fully  underwent  CFAE-ablation  from  September  2008  to
January  2010,  at  Kagoshima  University  in  Kagoshima,  Japan.
History of  pulmonary  vein  isolation  14
DVR, double (mitral and aortic) valve replacement; ECD, endo-
cardial cushion defect; LV, left ventricular; MVR, mitral valve
replacement; TOF, tetralogy of Fallot.
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ntiarrhythmic  drugs  or  at  least  3  months  after  cessation
f  amiodarone.  Heparin  (3000  IU  initial  bolus,  1000—2000  IU
ubsequent  boluses  as  needed  to  keep  the  activated  clotting
ime  >250  s)  was  administered  for  anticoagulation.
All  electroanatomic  maps  were  created  for  patients  who
ere  in  AF,  either  occurring  spontaneously  or  by  induction.
urst  pacing  utilizing  a  CS  catheter  to  a  lower  limit  of  1:1
apture  or  up  to  150  ms  was  used  to  induce  AF  occasionally
ith  a  0.01—0.02  g/kg/min  isoproterenol  infusion.  When
F  was  terminated  during  the  ablation  procedure  in  parox-
smal  AF  patients,  AF  was  re-induced  until  it  was  no  longer
nducible,  because  paroxysmal  AF  could  be  terminated  spon-
aneously.
An  electroanatomical  map  was  created  and  displayed  as
 voltage  map,  and  the  areas  of  CFAE  were  identiﬁed  manu-
lly,  tagged,  and  associated  with  the  atrial  anatomy  created
y  CARTO.  This  enabled  the  operator  to  associate  areas  of
FAE  with  the  left  atrium  (LA),  CS,  and  occasionally  the  right
trium,  thereby  identifying  target  sites  for  ablation.
Bipolar  recordings  were  ﬁltered  at  30—500  Hz,  and  the
FAE  was  deﬁned  as  follows:  (1)  fractionated  electrograms
omposed  of  2  or  more  deﬂections  and/or  a  perturbation
f  the  baseline  with  continuous  deﬂection  of  a  prolonged
ctivation  complex;  and  (2)  atrial  electrograms  with  a very
hort  cycle  length  (≤120  ms).
After  acquiring  the  voltage  map  associated  with  CFAE,
e  searched  the  areas  of  CFAE  referring  to  the  tagged
oints  because  CFAE  areas  have  temporal  spatial  stabil-
ty.  Radiofrequency  (RF)  applications  were  delivered  with  a
aximal  power  of  35  W  with  irrigation  rates  of  17—30  ml/min
3.5-mm  NaviStar  ThermoCool  catheters).  The  power  was
educed  to  15—25  W  in  the  posterior  LA,  or  in  the  CS.  An  8-
m  NaviStar  catheter  with  a  maximal  temperature  of  55 ◦C
t  the  catheter  tip  and  a  maximal  power  of  50  W  was  used
ntil  it  was  replaced  by  a  NaviStar  ThermoCool  catheter  in
pril  2009.
The  primary  endpoints  during  RF  ablation  were  either
omplete  elimination  of  areas  of  CFAE  or  conversion  of  AF
o  SR  with  or  without  injection  of  nifekalant  (0.3—0.6  mg/kg
ntravenously  over  10  min),  a  Class  III  antiarrhythmic  drug
imilar  to  ibutilide,  which  is  not  available  in  Japan.  If  the
rrhythmias  were  not  successfully  terminated,  internal  car-
ioversion  was  performed.valuation  of  PVI
VP  electrogram  recordings  using  a  circular  catheter  (Inquiry
ptima,  St.  Jude  Medical)  during  SR  before  and  after  CFAE-
P
I
o
Table  2  Comparison  of  mean  age,  termination  rate,  and  RF  pro
long-standing  AF.
Paroxysmal  AF  
(n =  54)  
Mean  age  61  ±  10  
Termination rate  53  (98%)  
RF time  (min)  55  ±  33  
Procedure time  (min)  222  ±  68  
Fluoroscopic time  (min)  33  ±  18  
AF, atrial ﬁbrillation; RF, radiofrequency.Y.  Iriki  et  al.
blation  were  analyzed  blindly  ofﬂine.  The  electrograms
ere  collected  and  measured  with  Prucka  (GE  Medical
ystems,  Inc.,  Milwaukee,  WI,  USA)  and  CARTO  mapping  sys-
ems.  Since  it  was  difﬁcult  to  assure  identical  placement  of
he  circular  catheter  before  and  after  CFAE-ablation,  and
ecause  the  PVP  could  be  delayed  (about  5—10  ms)  if  the
atheter  position  was  not  in  the  exact  same  place,  then  a  dif-
erence  in  PVP  of  30  ms  or  more  was  deﬁned  as  ‘‘delayed.’’
ollow-up  and  outcome
ost-procedure,  patients  continued  anticoagulation  with
arfarin  for  a  minimum  of  3  months.  Patients  were  fol-
owed  at  1,  3,  6,  and  12  months  post-ablation.  A  12-lead
lectrocardiogram  and  24-h  Holter  recording  were  done
outinely  in  all  patients  at  each  of  the  follow-up  visits.  Exter-
al  loop  recorders  were  used  to  conﬁrm  rhythms  for  any
atient-reported  suspicious  symptoms  outside  of  the  routine
ollow-ups.  Recurrences  were  based  upon  patient  reporting,
oop,  Holter  device,  and/or  electrocardiogram  detection.
o  patients  were  lost  to  follow-up,  and  all  underwent  the
equired  outpatient  visits  and  monitoring.
esults
ncidence  of  AF  termination  during  CFAE-ablation
F  was  converted  to  SR  in  53  (98%)  patients  with  paroxysmal
F  (16  [30%]  with  nifekalant),  in  28  (80%)  patients  with  per-
istent  AF  (16  [57%]  with  nifekalant),  and  in  6  (55%)  patients
ith  long-standing  persistent  AF  (5  [83%]  with  nifekalant).
hen  the  AF  was  ‘‘organized’’  or  changed  to  atrial  tachycar-
ia  or  ﬂutter,  we  also  ablated  the  points  which  showed  more
rganized  fractionated  potential  around  the  CFAE  areas  to
onvert  to  SR;  we  did  not  perform  linear  ablation  in  this
tudy  (Fig.  1).  The  remaining  patients  required  cardioversion
o  maintain  SR.
The  common  areas  of  the  CFAE  were  at  the  anterior
spect  of  the  right  PV  antrums,  the  posterior  aspect  of  the
eft  PV  antrums,  the  ridge  of  the  LA  appendage,  the  proxi-
al  CS,  and  the  posterior  septum  of  the  right  atrium.  The
ean  RF  time,  procedure  time,  and  ﬂuoroscopic  time  are
hown  in  Table  2.VI  before  and  after  CFAE-ablation
nternal  cardioversion  was  attempted  to  convert  AF  to  SR
nly  once;  however,  SR  was  not  maintained  during  the  study
cedure  and  ﬂuoroscopic  time  in  paroxysmal,  persistent,  and
Persistent  AF  Long-standing  AF
(n  =  35)  (n  =  11)
59  ±  12  49  ±  8
28  (80%)  6  (55%)
66  ±  34  74  ±  37
240  ±  73  278  ±  100
36  ±  16  38  ±  23
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Figure  1  Example  of  CARTO  voltage  maps  and  intracardiac
electrocardiograms  of  a  patient  with  persistent  atrial  ﬁbril-
lation (AF).  A  46-year-old  patient  with  persistent  AF  of  more
than  1  months’  duration.  AF  could  not  be  converted  to  sinus
rhythm without  cardioversion.  (a)  The  anteroposterior  (AP)
view of  the  CARTO  voltage  map  of  the  left  atrium  (LA)  and
coronary  sinus  (CS).  Pink  dots  represent  the  points  in  the
intracardiac  electrogram,  which  showed  complex  fractionated
atrial electrogram  (CFAE)  when  making  the  voltage  map  before
ablation.  Blue  dot  represents  the  area  of  the  mitral  valve
annulus.  Yellow  dot  represents  the  termination  point  of  atrial
tachycardia  (AT).  (b)  The  posteroanterior  (PA)  view  of  the
CARTO voltage  map.  (c)  The  right  upper  panel  shows  the  AP
view of  the  CARTO  map  mesh  image  of  the  LA  and  CS.  The
left upper  panel  shows  the  intracardiac  electrocardiogram
of the  bottom  of  the  right  superior  pulmonary  vein  (RSPV),
which  is  an  example  of  CFAE.  Eso  =  catheter  in  esophagus;
ABL-d  =  ablation  catheter  distal;  ABL-p  =  ablation  catheter
distal.  In  this  patient,  AF  was  changed  to  AT  (cycle  length
of 356  ms).  Our  targets  were  still  the  fractionated  potentials
after  AF  changed  to  AT,  but  the  electrograms  were  also
‘‘organized’’  (left  bottom  panel).  Bottom  panels  show  the
intracardiac  electrocardiograms  before  and  after  the  AT
termination  caused  by  radiofrequency  (RF)  application  to
the roof  of  the  LA  (yellow  dot,  arrow),  and  sinus  rhythm  was
evaluating  PVPs  before  CFAE-ablation  in  32  patients.  These
patients  were  excluded,  along  with  7  patients  who  were
absent  of  PVP  in  all  4  veins  due  to  previous  PVI(s).  In  215
PVs  among  the  remaining  61  patients  (42  paroxysmal  AF,  19
persistent  AF),  there  were  28  PVs  (13%)  in  which  the  interval
from  the  local  atrial  potential  to  PVP  was  prolonged  by  CFAE-
ablation.  Only  17  PVs  (8%)  were  inadvertently  isolated  by
CFAE-ablation.  Further,  in  26  of  61  patients  (43%;  17  paroxys-
mal  AF,  9  persistent  AF),  at  least  one  of  the  PVs  was  isolated
or  delayed.  Two  of  these  cases  are  illustrated  in  Figs.  1  and  2.
Outcomes
The  outcome  of  at  least  12  months  of  follow-up  of  all
patients  (23  ±  5  months)  was  65%  of  paroxysmal  (11%  with
drug),  54%  of  persistent  (37%  with  drug),  and  45%  of  long-
standing  persistent  AFs  (60%  with  drug)  in  one  session.  We
determined  the  procedure  was  a  failure  when  a  patient  still
had  arrhythmias  and  wanted  to  have  a second  session,  even
if  the  patient  had  no  arrhythmias  with  antiarrhythmic  drugs,
but  had  them  without  drugs.
Additionally,  regarding  the  patients  who  had  at  least  one
PV  isolated  or  who  had  delayed  PVP,  12  of  17  (71%)  parox-
ysmal  AF  patients  and  5  of  9  (56%)  persistent  AF  patients
were  free  from  atrial  arrhythmias,  including  with  drug  in
one  session.  There  was  no  difference  between  the  patients
whose  PVP  was  effected  by  CFAE  ablation  or  not  (p  =  0.17  in
paroxysmal,  p  =  0.78  in  persistent).
Procedure  complications
There  were  no  complications  (e.g.  cerebrovascular  acci-
dent,  high-grade  atrioventricular  nodal  block,  hemoperi-
cardium  treated  with  pericardiocentesis,  esophageal-LA
ﬁstula,  clinical  PV  stenosis,  or  vascular  complications  at  the
femoral  puncture  site)  in  this  study.
Outcomes  compared  with  PVI
Even  though  our  study  was  not  designed  to  compare  CFAE-
ablation  with  PVI  for  the  treatment  of  AF,  we  believe  that
it  will  give  some  insight  into  the  relative  efﬁcacy  and  safety
between  these  2  strategies.  Thus,  we  compared  the  current
study’s  results  with  our  previously  performed  PVI  (circumfer-
ential  PV  antrum  ablation)  in  our  institution  in  55  patients
maintained  after  this  RF  application.  The  RF  point  was  in  the
same area  where  we  ablated  the  AF.  Any  liner  ablations  were  not
attempted  to  terminate  AT.  (d)  The  inner  view  of  the  left  inferior
pulmonary  vein  (LIPV).  RF  was  applied  to  the  areas  of  CFAE  (red
dots), which  were  not  continuous.  (e)  The  intracardiac  elec-
trogram  recordings  of  LIPV  before  and  after  ablation  guided  by
CFAE.  PV  potential  (PVP)  was  absent  after  CFAE-ablation.  PVP
of left  superior  and  right  inferior  PVs  was  absent  also,  but  PVP
of the  right  superior  PV  was  not  affected  by  CFAE-ablation.  The
mainly ablated  areas  were:  (1)  lower  septum,  (2)  ridge  of  the
LA appendage,  (3)  LA  roof,  (4)  proximal  CS,  (5)  posterior  aspect
of the  left  PVs,  and  (6)  bottom  of  LA  posterior  wall.  RF  duration
was 137  min.  (For  interpretation  of  the  references  to  color  in
this ﬁgure  legend,  the  reader  is  referred  to  the  web  version  of
the article.)
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Figure  2  Example  of  CARTO  voltage  maps  and  intracardiac
electrocardiograms  of  a  patient  with  paroxysmal  atrial  ﬁbril-
lation  (AF).  A  50-year-old  patient  with  paroxysmal  AF.  (a)  The
anteroposterior  (AP)  view  of  the  CARTO  voltage  map  of  the  left
atrium (LA),  after  AF  was  induced  by  coronary  sinus  (CS)  rapid
pacing  (230  ms).  Pink  dots  represent  the  points  in  the  intrac-
ardiac electrogram,  which  showed  complex  fractionated  atrial
electrogram  (CFAE)  when  making  the  voltage  map  before  abla-
tion. Yellow  dot  represents  the  termination  point  of  AF.  (b)  The
posteroanterior  (PA)  view  of  the  CARTO  voltage  map.  (c)  The
right panel  shows  the  AP  view  of  the  CARTO  map  mesh  image  of
the LA.  The  left  panel  shows  the  intracardiac  electrocardiogram
of anterior  aspect  of  the  right  superior  pulmonary  vein  (RSPV),
which  is  an  example  of  CFAE.  Radiofrequency  (RF)  applications
to anterior  aspect  of  RSPV  (yellow  dot,  arrow)  terminated  AF,
but re-induced  by  rapid  atrial  pacing.  Eso  =  catheter  in  esopha-
gus; ABL-d  =  ablation  catheter  distal;  ABL-p  =  ablation  catheter
proximal.  (d)  Left  panel  shows  the  PA  view  of  the  CARTO  map
with  paroxysmal  AF  and  21  with  persistent  AF  (no  patients
with  long-standing  persistent  AF  had  PVI).
Table  3  summarizes  and  compares  the  outcomes  of  the
2  ablative  approaches.  For  patients  with  paroxysmal  AF,
the  outcome  of  the  2  strategies  was  similar.  After  1  ses-
sion,  the  success  rate  was  73%  in  the  PVI  group  versus  65%
in  the  CFAE-ablation  group  in  the  current  study  (p  =  0.22).
However,  for  patients  with  persistent  AF,  after  1  session,
only  33%  were  free  of  AF/atrial  tachyarrhythmias  in  the
PVI  group  compared  with  54%  in  the  CFAE-ablation  group
(p  <  0.01).
Discussion
Catheter  ablation  of  AF  by  targeting  CFAE  as  the  sole  strat-
egy  remains  controversial.  Nademanee  et  al.  demonstrated
that  this  approach  is  very  effective  at  both  terminating  AF
in  the  electrophysiology  laboratory  as  well  as  maintaining
SR;  however,  the  same  results  have  not  been  replicated  in
other  studies  to  date.  The  ﬁndings  from  our  study  clearly
conﬁrm  that  CFAE-guided  AF  ablation  is  indeed  as  effective
as  PVI  in  patients  with  paroxysmal  AF  and  is  more  effective
in  persistent  AF,  as  described  below.
Major  ﬁndings
First,  CFAE-ablation  resulted  in  AF  termination  in  a  high
percentage  of  patients  in  our  study.  AF  was  terminated  in
98%  of  patients  with  paroxysmal  AF,  80%  of  patients  with
persistent  AF,  and  55%  of  patients  with  long-standing  AF,
even  though  nifekalant  was  occasionally  injected  to  high-
light  the  residual  CFAE  sites  instead  of  ibutilide.  Second,
the  PVP  was  found  to  be  inadvertently  isolated  during  CFAE-
ablation  in  only  8%  of  PVs.  Third,  CFAE-ablation  resulted
in  a  prolongation  (>30  ms)  of  the  interval  from  the  local
atrial  potential  to  the  PVP  in  13%  of  PVs.  Last,  in  26  of  61
patients  (43%),  the  PVP  was  delayed  or  at  least  one  PV  was
isolated,  and  the  outcome  of  these  patients  was  similar  to
the  patients  whose  PVP  was  not  affected  in  all  4  PVs  by  CFAE
ablation.
Although  the  PV  was  unintentionally  isolated  by  CFAE-
ablation  in  only  8%  of  PVs,  AF  was  successfully  terminated
in  virtually  all  patients  with  paroxysmal  AF,  and  in  the  major-
ity  of  patients  with  persistent  and  long-standing  AF,  without
mesh  image  of  the  LA.  Right  panels  show  the  intracardiac  elec-
trocardiograms  before  and  after  the  AF  termination  caused  by
RF application  to  the  LA  posterior  wall  (yellow  dot,  arrow),  and
AF was  no  longer  induced  after  this  RF  application.  (e)  The  inner
view of  the  left  superior  PV  (LSPV).  RF  was  applied  to  the  areas
of CFAE  (red  dots),  which  were  not  continuous.  (f)  The  intrac-
ardiac electrogram  recordings  of  the  LSPV  before  and  after
ablation  guided  by  CFAE.  PV  potential  (PVP)  was  absent  after
CFAE-ablation.  The  PVP  of  left  inferior  PV  was  absent  also,  but
the PVP  of  right  PVs  was  not  affected  by  CFAE-ablation.  The
mainly  ablated  areas  were:  (1)  ridge  of  the  LA  appendage,  (2)
middle  to  bottom  of  the  LA  septum,  (3)  area  of  ligament  of
Marshall,  and  (4)  anterior  aspect  of  the  RSPV.  RF  duration  was
116 min.  (For  interpretation  of  the  references  to  color  in  this
ﬁgure legend,  the  reader  is  referred  to  the  web  version  of  the
article.)
Unintentional  PV  isolation  by  CFAE  ablation  283
Table  3  Comparison  of  the  outcome  between  two  strategies.
PVI  CFAE
(n =  76)  (n  =  100)
Mean  age 57  ±  11  59  ±  11
Paroxysmal/persistent/long-standing  AF  55/21/0  54/35/11
Hypertensive  heart  disease  8  (11%)  18  (18%)
LA volume  index  (ml/m2)  33.7/41.5/—  37.1/43.5/42.1
Success rate  in  one  session 75%/33%/— 65%/54%*/45%
AF, atrial ﬁbrillation; LA, left atrium; PVI, pulmonary vein isolation; CFAE, complex fractionated atrial electrograms.
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s* Success rate in persistent AF by CFAE-ablation was signiﬁcantly
cardioversion.  This  study  conﬁrms  the  ﬁndings  of  Nadema-
nee  et  al.  [7,16,17]  that  CFAE-ablation  yielded  a  very  high
rate  of  acute  AF  termination  during  the  ablative  procedure;
however,  these  ﬁndings  are  different  from  those  of  other
investigators,  who  found  a  very  low  termination  rate  during
CFAE-ablations  [6,27].
There  were  some  reports  about  the  learning  curve  of
PVI  [28,29],  but  there  have  not  been  any  reports  about
the  learning  curve  of  CFAE  ablation.  Then  although  the
reasons  behind  the  differences  in  the  acute  termination
rate  of  the  CFAE-ablation  remain  unknown,  one  must
recognize  that  CFAEs  are  more  challenging  than  PVI  for
several  reasons.  First,  performing  CFAE-ablation  requires
detailed  mapping  of  both  the  atria  and  CS  to  search
for  CFAE  target  sites,  whereas  anatomical-based  PVI  is
more  stable  because  it  has  speciﬁc  PVs  as  the  target
sites.  Other  complexities  include  the  knowledge  of  dis-
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Table  4  Comparison  of  outcomes  of  different  ablation  approache
and persistent  AF.
Investigators  [Ref.
#],  ablation
technique
#  of  Patients  Age  (yrs)  Procedure/
ﬂuoroscopic
time  (min)
PAF
Wilber  et  al.  [31],
PVI
103  55  NA  
Jais et  al.  [32],
PVI +  liner
lesions
53  50  ±  11  168/50  
Iriki et  al.,  CFAE
alone
45  61  ±  10  221/33  
Verma et  al.  [33],
APVI  +  CFAE
60  56  ±  9  188/84  
Persistent/permanent
Haissaguerre  et  al.
[34], PVI  +  Liner
60 53  ±  9  264/84  
Oral et  al.  [27],
APVI  +  CFAE
50  62  ±  8  254/59  
Iriki et  al.,  CFAE
alone
36  57  ±  12  256/39  
Verma et  al.  [33],
APVI  +  CFAE
40  56  ±  9  188/84  
AF, atrial ﬁbrillation; APVI, antrum pulmonary vein isolation; CFAE, 
isolation; RF, radiofrequency.er than that by PVI (p < 0.01).
ribution  of  CFAE  areas,  the  type  of  potential  pattern
hat  must  be  ablated  [30], and  the  fact  that  the  sites
hat  harbor  good  CFAE  targets  for  ablation  tend  to  have
reas  with  a  high  density  of  CFAE  points  cluttering  in  the
ame  location.  This  in  turn  requires  several  repeated  RF
pplications  over  the  areas  juxtapositioned  to  the  target
ites  in  order  to  eliminate  all  CFAEs  and  typically  results
n  a high  density  of  ablation  points  at  the  target  sites
Figs.  1  and  2).  In  contrast,  the  points  ablated  by  electro-
hysiologists  during  CFAE-ablation  in  other  studies  looked
parse  [6,27]  and  appeared  differently  than  those  in  our
tudy.
In  any  event,  our  high  rate  of  success  in  acute  termination
ranslates  into  a  very  good  long-term  outcome.  After  one
ession  of  AF  ablation  and  after  follow-up  of  a  minimum  of  12
onths,  65%  of  paroxysmal  AF  patients,  54%  of  persistent  AF
atients,  and  45%  of  long-standing  AF  patients  remain  free
s  that  incorporated  CFAE-ablation  in  patients  with  paroxysmal
RF  time  (min)  Acute  AF
termination
Long-term  success
(only1/2  or  more
ablations)
NA  NA  NA/66%
NA  —  57%/89%
54  ±  33  98%  (with
nifekalant)
72%/—
57  ±  12  NA  87%/—
NA  87%  60%/95%
54  ±  19  34%  (with
ibutilide)
—/60%
68  ±  34  76%  (with
nifekalant)
47%/—
57  ±  12  NA  82%/—
complex fractionated atrial electrogram; PVI, pulmonary vein
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f  atrial  arrhythmias.  Our  study  is  comparable  with  that  of
ademanee  et  al.,  and  interestingly  highlights  their  previous
bservation  that  the  clinical  outcomes  after  one  session  are
s  good  as  PVI  in  paroxysmal  AF  patients  and  much  better
n  persistent  AF  patients.  Table  4  summarizes  these  results
27,31—34].
There  may  be  concern  about  the  use  of  nifekalant  to
ighlight  the  residual  CFAE  sites,  because  nifekalant  could
erminate  AF  by  itself.  But  a  previous  report  demonstrated
hat  the  use  of  ibutilide  was  not  associated  with  the  outcome
35]  and  we  also  conﬁrmed  that  in  the  use  of  nifekalant.  The
ossible  role  of  nifekalant  is  to  highlight  the  residual  CFAE
ites  by  prolonging  the  cycle  length  and  ‘‘organizing’’  the
F,  and  the  potential  of  CFAE  is  also  ‘‘organizing’’  (Fig.  1c,
eft  bottom  panel),  and  then  the  residual  CFAE  sites  were
asy  to  be  detected.
Our  observation  clearly  suggests  that  CFAE-ablation  could
ield  very  good  long-term  outcomes  for  AF  patients  with-
ut  the  need  for  PVI.  The  Heart  Rhythm  Society  Expert
onsensus  Statement  stated  that  PVI  is  a  cornerstone  of
F  ablation,  especially  for  patients  with  paroxysmal  AF
26].  Our  results  clearly  offer  a  different  view  point  that
F  could  be  effectively  treated  without  having  to  iso-
ate  all  4  veins.  However,  this  does  not  imply  that  PVs
re  not  important  in  the  pathophysiological  mechanisms  of
F  genesis,  especially  in  patients  with  paroxysmal  AF.  A
ajority  of  electrophysiologists  may  believe  that  the  dis-
al  of  the  PVs  are  the  main  source  of  AF  trigger,  then
VI  is  mandatory.  But  there  were  only  a  few  premature
trial  contractions  after  CFAE  ablation.  Then  we  estimate
hat  the  areas  of  triggering  and  perpetuating  of  AF  are
imilar  and  both  show  fractionated  potential.  We  did  not
onclude  that  the  PVI  was  not  appropriate  to  the  ﬁrst
ine  therapy  for  paroxysmal  AF,  and  CFAE  ablation  is  chal-
enging  in  the  beginning,  but  once  electrophysiologists  get
sed  to  CFAE  ablation,  they  do  not  have  to  struggle  to
ecide  the  strategies  of  AF  ablation  even  in  the  patients
ith  structural  heart  disease,  large  LA  volume,  and  those
ho  have  a  history  of  PVI  and/or  persistent/longstanding
F.
Chen  et  al.  reported  that  during  PVI,  extending  the  abla-
ion  lesions  by  up  to  10  mm  from  the  PV  ostia  might  cover
ost  high-frequency  CFAEs  around  the  PV  antrums,  and  that
igh-frequency  CFAEs  were  more  often  located  in  the  PV
stia  in  patients  with  paroxysmal  AF  than  in  patients  with
ersistent  AF  [36]. In  this  study,  CFAE-ablation  resulted  in
 prolongation  (>30  ms)  of  the  interval  from  the  local  atrial
otential  to  the  PVP  in  13%  of  PVs.  In  26  of  61  (43%)  patients,
he  interval  from  the  local  atrial  potential  to  the  PVP  was
rolonged  or  at  least  1  of  the  4  PVs  was  isolated.
These  results  correspond  with  those  reported  by  Chen
t  al.  [36]. The  areas  around  PVs  are  relatively  more  impor-
ant  in  the  underlying  electrophysiologic  mechanism  of
aroxysmal  AF  compared  to  that  of  persistent  AF.  The  dis-
ribution  of  CFAE  areas  included  the  anterior  aspect  of  the
ight  PVs,  the  posterior  aspect  of  the  left  PVs,  and  the  ridge
f  the  LA  appendage  [7,30]. The  ridge  of  the  LA  appendage
ncludes  the  area  between  the  left  superior  PV  and  the
A  appendage.  As  this  area  is  usually  ablated  during  PVI,
t  is  possible  that  the  PVI  may  unintentionally  ablate  the
FAE  areas,  which  may  be  why  PVI  eliminated  AF  in  some
atients.
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Consequently,  the  outcome  of  PVI  is  similar  to  that  of  the
FAE-ablation  in  paroxysmal  AF,  despite  the  large  difference
n  the  outcome  of  persistent  AF.  We  speculate  that  these
ndings  may  explain  why  additional  CFAE-ablation  after  PVI
ight  not  improve  the  success  rate  compared  with  PVI  alone
19].
Although  our  outcomes  for  both  acute  termination  and
ong-term  maintenance  of  SR  in  paroxysmal  AF  patients  are
omparable  to  those  of  Nademanee  et  al.,  the  outcome  of
his  study  in  patients  with  persistent  and  long-standing  AF
as  not  as  positive  as  previous  reports  [7,16,17,30]. The
easons  we  speculate  are  as  follows:  (1)  the  cases  in  the
resent  study  were  the  ‘‘initial’’  100  cases  of  6  doctors  who
ad  some  experience  with  PVI,  but  not  with  CFAE-ablation;
2)  we  could  only  terminate  AF  in  55%  of  patients  with
ong-standing  AF;  and  (3)  to  avoid  complications  (cerebral
nfarction),  at  that  time  the  maximum  power  was  35  W  in
he  3.5-mm  ThermoCool  NaviStar  catheter,  and  50  W  in  the
-mm  NaviStar  catheter  to  avoid  char  formation.
The  outcome  of  PVI  previously  performed  in  our  institute
as  73%  in  paroxysmal  AF  and  33%  in  persistent  AF  patients  in
ne  session  to  be  adjusted  the  following  period,  even  though
he  patient  characteristics  were  less  severe  than  those  in  the
FAE  group.
Although  this  was  not  a  double-blind  study,  the  clinical
utcome  after  one  session  was  as  good  as  in  paroxysmal
nd  much  better  than  persistent  AF  with  CFAE-ablation  com-
ared  to  PVI.  According  to  this  study,  PVI,  especially  for  all
 veins,  did  not  appear  to  be  mandatory.  Combined  therapy
f  PVI  and  CFAE  could  yield  a  better  outcome,  even  though
here  would  be  a  longer  procedure  and  ﬂuoroscopic  time
sing  the  same  operators.
Verma  et  al.  [37]  reported  that  the  outcome  of  combined
herapy  improved  compared  with  PVI,  but  others  reported
hat  there  was  no  difference  [38,39].  These  patients  had
ifferent  backgrounds,  so  we  could  not  compare  these  stud-
es  directly,  but  the  former  reported  a  better  termination
ate  than  the  latter  study.  According  to  these  studies,  a  high
ate  of  termination  may  guarantee  a  good  outcome  even  in
ombined  therapy.
tudy  limitations
nalysis  required  exclusion  of  39%  of  the  patients  in  which
R  could  not  be  maintained  before  ablation  and/or  in  which
VP  of  all  4  veins  was  absent  due  to  previous  PVI(s).  It  was
ifﬁcult  to  maintain  SR  during  recording  of  the  PVP  before
FAE-ablation,  especially  in  patients  with  persistent/long-
tanding  AF,  because  movement  of  the  circular  catheter
ften  triggered  re-initiation  of  AF.  PVs  might  be  more  likely
o  be  inadvertently  isolated  by  CFAE-ablation  in  patients
ith  persistent  AF  than  paroxysmal  AF  because  there  are
ore  RF  points  in  ablation  for  patients  with  persistent  AF
han  paroxysmal  AF.
However,  there  was  not  a  big  difference  between  the  two
roups;  the  number  of  the  patients  who  had  at  least  one
V  isolated  or  delayed  PVP  was  17  of  42  (40%)  in  paroxys-
al  and  9  of  19  (47%)  in  persistent  AF.  And  the  outcome  of
he  patients  with  at  least  one  PV  isolated  or  delayed  PVP
as  similar  to  the  patients  whose  PVP  was  not  affected  in
ll  4  PVs  by  CFAE  ablation.  Therefore,  even  though  no  PVP
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information  was  available  from  the  remaining  39  excluded
patients,  this  should  not  signiﬁcantly  bias  the  results.
Conclusions
Our  data  demonstrate  that  areas  which  consistently  har-
bor  CFAE  are  important  in  maintaining  AF,  and  show  that
the  strategy  of  ablating  such  areas  is  an  effective  approach
in  terminating  AF  and  maintaining  SR  without  the  need  to
isolate  all  4  PVs.  Our  study  ﬁndings  undoubtedly  will  be  con-
troversial,  but  hopefully  will  lead  to  further  studies  that  will
provide  an  AF  ablative  approach,  which  will  yield  the  best
clinical  outcomes  and  lowest  procedural  risks.
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